We report the results of an association study of melanoma that is based on the genome-wide imputation of the genotypes of 1,353 cases and 3,566 controls of European origin conducted by the GenoMEL consortium. This revealed an association between several SNPs in intron 8 of the FTO gene, including rs16953002, which replicated using 12,313 cases and 55,667 controls of European ancestry from Europe, the USA and Australia (combined P = 3.6 × 10 −12 , per-allele odds ratio for allele A = 1.16). In addition to identifying a new melanomasusceptibility locus, this is to our knowledge the first study to identify and replicate an association with SNPs in FTO not related to body mass index (BMI). These SNPs are not in intron 1 (the BMI-related region) and exhibit no association with BMI. This suggests FTO's function may be broader than the existing paradigm that FTO variants influence multiple traits only through their associations with BMI and obesity.
rare, highly penetrant variants, at least 11 common variants of lower effect identified by genome-wide association studies (GWAS) 8, 9 (many related to pigmentation or nevus count 10, 11 ) and mutations of intermediate effect in the MITF gene identified through a candidate-gene approach in indidviduals affected with melanoma and renal-cell carcinoma 12 and sequencing genomes of multiply affected melanoma families 13 .
The FTO gene was first found to be associated with obesity in GWAS of type 2 diabetes 14 and obesity 15, 16 . Most 14, [17] [18] [19] [20] [21] but not all 22, 23 studies found no association between FTO and type 2 diabetes risk after adjustment for BMI. The strongest associations were with variants in intron 1 of FTO, but linkage disequilibrium (LD) stretches across introns 1 and 2 and exon 2. No SNP outside intron 1 has been previously associated with any trait, and no SNP in intron 1 has been associated with any trait unrelated to BMI.
The GenoMEL consortium focuses on genetic susceptibility to melanoma and has conducted two melanoma GWAS (Phase 1 and Phase 2) using samples from populations of European or Israeli ancestry 9, 11 . Genotypes of the 1,373 cases and 3,571 controls from Phase 1 of the GenoMEL GWAS of melanoma 9 were imputed, giving 2.6 million SNPs, each tested for association with melanoma risk using A variant in FTO shows association with melanoma risk not due to BMI l e t t e r s geographic region as a covariate (Online Methods). The most significant SNP in a region not previously associated with melanoma was in FTO. Three SNPs in intron 8 of FTO were significant at P < 10 −5 , the most significant being rs16953002 (P = 5.59 × 10 −6 , per-allele odds ratio (OR) = 1.33, risk allele A, risk allele frequency = 0.19) and rs12596638 (P = 4.43 × 10 −6 , per-allele OR = 1.34, risk allele A, risk allele frequency = 0.19; in strong LD, r 2 = 0.96). We confirmed imputation quality by subsequent genotyping (Online Methods).
Following this finding, we imputed a region 1 Mb either side of rs16953002 for 1,449 cases and 4,043 controls in GenoMEL melanoma GWAS Phase 2 (ref. 11) and regressed SNP dosage on melanoma casecontrol status with geographic region as a covariate. In this analysis, we genotyped rs16953002 (P = 0.015, OR = 1.16) and imputed rs12596638 (P = 0.023, OR = 1.15). Combining all GenoMEL GWAS data gave five SNPs within 18 kb with P < 10 −4 in intron 8 of FTO and over 250 kb from the closest SNP associated with BMI ( Fig. 1) .
We sought replication (mainly using existing GWAS data) using other samples of European ancestry from Europe, Australia and the United States, totaling 10,865 cases and 51,624 controls (Supplementary Table 1 ). All replication samples combined exhibited association between rs16953002 and melanoma with an allelic OR of 1.14, P = 4.8 × 10 −9 , with all sample sets showing OR estimates in the same direction as the original finding and with no evidence of heterogeneity. When we combined these data with the GenoMEL sample data, we observed strong evidence of association with melanoma: P = 3.6 × 10 −12 , per-allele OR = 1.16, 95% confidence interval (1.11, 1.20) , and no evidence of heterogeneity (I 2 = 0; Online Methods, Fig. 2 and Table 1 ).
BMI has, at best, a weak effect on risk of melanoma 24, 25 . Given the clear association between variants in FTO and BMI, we investigated whether the melanoma-associated SNPs showed any association with BMI or, conversely, whether the known BMI-associated SNPs showed any association with melanoma.
BMI data were available for 37% of cases and 59% of controls (many of the GenoMEL samples and seven of the replication sets; Supplementary Table 1), with additional controls collected in Iceland to give 63,518 samples from Iceland with BMI data and 14,222 from elsewhere with BMI data. Adjusting log(BMI) for age and age-squared, and regressing this on SNP genotype, with case-control status and sex as covariates, there was no significant association between rs16953002 and BMI with a combined P value of 0.15 ( Supplementary Fig. 1) . A more powerful data set for assessing BMI-SNP associations is that of the GIANT consortium 26 (http://www.broadinstitute.org/collaboration/giant/ index.php/GIANT_consortium_data_files). In the GIANT consortium data, allele A of rs16953002 was very weakly associated with decreased BMI (P = 0.0156 in 123,852 individuals, indicating at most a very small effect size).
In contrast, the genotyped SNP in the FTO region that was most strongly associated with BMI in the GenoMEL data was rs8050136 (P = 8.7 × 10 −56 in all our data sets combined; Supplementary Figs. 2 and 3). In the GIANT data set this association with BMI reached P = 1 × 10 −59 .
We also found very little LD between the two SNPs (r 2 = 0.000039 in 35,583 Icelandic controls and r 2 < 0.006 in every other control set). In a recent study in which FTO was sequenced, only SNPs in intron 1 were associated with BMI 27 . It could be that the rs16953002-BMI association in the GIANT data is due to a very well-powered data set picking up on slight LD. The great difference between the strength of association between BMI at rs8050136 and at rs16953002 can clearly be seen in a plot of the GIANT results ( Supplementary Fig. 4 ).
rs8050136 was not associated with melanoma, having a combined meta-analysis P value with GenoMEL of 0.19 (per-allele OR = 1.02; Supplementary Fig. 5 ). Therefore, from our data, the known BMIrelated SNPs were associated with BMI but not with melanoma risk, and the melanoma-associated SNPs exhibited no evidence of association with BMI ( Table 1) . We also found no association between melanoma risk and adjusted BMI in the GenoMEL data (P = 0.96). Figure 1 Results of stratified trend tests of imputed data for association with melanoma in region around FTO in GenoMEL Phase 1 and 2 data combined. −log 10 P values for association between SNPs in the region of FTO and melanoma case-control status are shown adjusted for geographic region. Color of points indicates extent of LD with rs16953002 (indicated by purple square). SNPs genotyped in all GenoMEL samples are plotted as circles, SNPs imputed in all samples as crosses and SNPs genotyped in some samples and imputed in others (as a result of chip differences) as squares. Positions of genes are given under the graph, and estimated recombination rates given by the blue line along the bottom, with scale on the right. Plot was produced using LocusZoom 39 . npg l e t t e r s
The association between rs16953002 and melanoma risk was consistent across geographic regions (Fig. 2 and Supplementary Fig. 6 ), and we found no significant difference in effect across subsets of the GenoMEL data defined by sex, tumor site, family history, early onset of disease and multiple primary tumors or association with any established melanoma-related trait (nevus count or sun sensitivity; data not shown). The association between rs16953002 and melanoma risk persisted in the subset of samples with BMI recorded even after adjusting for BMI (P = 0.01) despite a substantial reduction in sample size (Supplementary Table 2 and Supplementary Note).
We split the GenoMEL data into quartiles defined by adjusted BMI of controls and regressed case/control status on rs16953002 with sex as a covariate in each quartile. The association was stronger for those samples in the first quartile (lowest BMI) than those in the other quartiles (OR = 1.66, P = 3.00 × 10 −5 versus maximum OR = 1.03, minimum P = 0.82; Supplementary Fig. 7) , a difference that was significant (P = 0.0005). This is consistent with rs16953002 only being associated with melanoma risk in those people with low BMI. When we attempted to replicate the results defining BMI quartiles in each population, samples collected in Australia exhibited a similar effect (P = 0.003), but samples collected in other countries outside of the UK gave more equivocal results (Supplementary Fig. 7 ; P = 0.6 for all replicate samples and P = 0.06 with GenoMEL samples included). However, in the nine replication studies for which BMI data were available, rs16953002 always had the greatest association with melanoma risk for those in quartile 1 or 2.
Although the functional effect(s) of FTO is far from understood, evidence points to a variety of possible effects on BMI-related traits. However, a loss-of-function mutation in FTO caused gross developmental defects in nine members of a Palestinian family, suggesting a broader function for FTO 28 .
FTO has been associated with end-stage renal disease 29 , acute coronary syndrome 30 , myocardial infarction 31 , all-cause mortality 32 , Alzheimer's disease 33 and osteoarthritis 34 . Even after adjustment for BMI, some BMI-related traits exhibit association with FTO variants, but it may be that BMI simply correlates with a weight-related factor that acts more directly on the trait of interest. Given that BMI is a risk factor for many cancers, the BMI-related SNPs in intron 1 of FTO have been studied in some of these cancers. A study of lung, kidney and upper aero-digestive cancers revealed no significant effect overall after correction for multiple testing 35 . The largest study of FTO and endometrial cancer found an association with a known BMI-associated SNP (P = 0.01) 36 that disappears after adjustment for BMI.
Thus, there is little evidence of variants in FTO being associated with any trait unrelated to BMI. It may be that the melanoma-associated SNPs are in LD with functional SNPs outside of FTO, but given the low level of LD in the region (Fig. 1) this seems unlikely. It should be noted that our most significant SNP, rs16953002, is only 31 kb from exon 9 of FTO, over 146 kb from exon 8 of FTO and over 202 kb from the nearest other gene, IRX3. SNPs overlapping regulatory elements, such as transcription factor-binding sites, can be identified using the recent Encyclopedia of DNA Elements (ENCODE) data as well other data sources 37, 38 . In these data for the FTO gene, 2,148 SNPs have been identified, only eight of which reach the highest score possible without expression quantitative trait locus (eQTL) data (score 2a: 'likely to affect binding'). Six of these SNPs are in intron 1, the location of most of the BMI-associated SNPs, five of these in a 5.4-kb region less than 1 kb from rs8050136. The other two SNPs are 13 kb apart from one another in intron 8 and, notably, one of these is rs16953002, the melanoma-associated SNP (Supplementary Note).
In conclusion, this is the first time to our knowledge that any variant in FTO has been shown to have a replicable association with a trait without being associated with BMI. It is also the first time that any variant in FTO outside intron 1 has been shown to have any association with any trait. As such, this will be of interest to researchers in the fields of both cancer genetics and obesity research.
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